Added value of F-florbetaben amyloid PET in the diagnostic workup of most complex patients with dementia in France: A naturalistic study.

Date publication

mars 2018

Journal

Alzheimer's & dementia : the journal of the Alzheimer's Association

Auteurs

Membres identifiés du Cancéropôle Est :
Pr VERGER Antoine

Tous les auteurs :
Ceccaldi M, Jonveaux T, Verger A, Krolak-Salmon P, Houzard C, Godefroy O, Shields T, Perrotin A, Gismondi R, Bullich S, Jovalekic A, Raffa N, Pasquier F, Semah F, Dubois B, Habert MO, Wallon D, Chastan M, Payoux P, ,Stephens A, Guedj E

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29107051

Résumé

Although some studies have previously addressed the clinical impact of amyloid positron emission tomography (PET), none has specifically addressed its selective and hierarchical implementation in relation to cerebrospinal fluid analysis in a naturalistic setting.

Mots clés

Alzheimer's disease, Amyloid imaging, Clinical practice, Diagnosis, Florbetaben, Patient management

Référence

Alzheimers Dement. 2018 Mar;14(3):293-305